245 related articles for article (PubMed ID: 15792359)
1. The catalytically active secretory phospholipase A2 type IIA is involved in restenosis development after PTCA in human coronary arteries and generation of atherogenic LDL.
Korotaeva AA; Samoilova EV; Kaminny AI; Pirkova AA; Resink TJ; Erne P; Prokazova NV; Tkachuk VA; Chazov EI
Mol Cell Biochem; 2005 Feb; 270(1-2):107-13. PubMed ID: 15792359
[TBL] [Abstract][Full Text] [Related]
2. [Serum level of secretory phospholipase A2 (sPLA2) as a predictor of restenosis after coronary angioplasty].
Korotaeva AA; Provatorov SI; Samoĭlova EV; Kaminnyĭ AI; Sumarokov AB; Pirkova AA; Samko AN; Prokazova NV
Ter Arkh; 2002; 74(4):12-5. PubMed ID: 12043230
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
Luchtefeld M; Bandlow N; Tietge UJ; Grote K; Pfeilschifter J; Kaszkin M; Beck S; Drexler H; Schieffer B
Atherosclerosis; 2007 Sep; 194(1):62-70. PubMed ID: 17069818
[TBL] [Abstract][Full Text] [Related]
4. Secretory phospholipases A2 induce neurite outgrowth in PC12 cells through lysophosphatidylcholine generation and activation of G2A receptor.
Ikeno Y; Konno N; Cheon SH; Bolchi A; Ottonello S; Kitamoto K; Arioka M
J Biol Chem; 2005 Jul; 280(30):28044-52. PubMed ID: 15927955
[TBL] [Abstract][Full Text] [Related]
5. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation.
Hanasaki K; Yamada K; Yamamoto S; Ishimoto Y; Saiga A; Ono T; Ikeda M; Notoya M; Kamitani S; Arita H
J Biol Chem; 2002 Aug; 277(32):29116-24. PubMed ID: 12021277
[TBL] [Abstract][Full Text] [Related]
6. New phospholipase A(2) isozymes with a potential role in atherosclerosis.
Murakami M; Kudo I
Curr Opin Lipidol; 2003 Oct; 14(5):431-6. PubMed ID: 14501581
[TBL] [Abstract][Full Text] [Related]
7. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
Leitinger N; Watson AD; Hama SY; Ivandic B; Qiao JH; Huber J; Faull KF; Grass DS; Navab M; Fogelman AM; de Beer FC; Lusis AJ; Berliner JA
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1291-8. PubMed ID: 10323782
[TBL] [Abstract][Full Text] [Related]
8. Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition.
Ghesquiere SA; Gijbels MJ; Anthonsen M; van Gorp PJ; van der Made I; Johansen B; Hofker MH; de Winther MP
J Lipid Res; 2005 Feb; 46(2):201-10. PubMed ID: 15576846
[TBL] [Abstract][Full Text] [Related]
9. Secretory PLA2 inhibitor indoxam suppresses LDL modification and associated inflammatory responses in TNFalpha-stimulated human endothelial cells.
Sonoki K; Iwase M; Sasaki N; Ohdo S; Higuchi S; Takata Y; Iida M
Br J Pharmacol; 2008 Apr; 153(7):1399-408. PubMed ID: 18264128
[TBL] [Abstract][Full Text] [Related]
10. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation.
Wooton-Kee CR; Boyanovsky BB; Nasser MS; de Villiers WJ; Webb NR
Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):762-7. PubMed ID: 14962950
[TBL] [Abstract][Full Text] [Related]
11. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA?
Kanemitsu S; Takekoshi N; Matsui S; Tsugawa H; Ohkubo S; Kitayama M; Matsuda T; Senma J; Masuyama K; Yamagata T; Murakami E
Ther Apher; 1998 Feb; 2(1):65-70. PubMed ID: 10227791
[TBL] [Abstract][Full Text] [Related]
12. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2.
Pruzanski W; Lambeau L; Lazdunsky M; Cho W; Kopilov J; Kuksis A
Biochim Biophys Acta; 2005 Sep; 1736(1):38-50. PubMed ID: 16122976
[TBL] [Abstract][Full Text] [Related]
13. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty.
Watanabe K; Sekiya M; Ikeda S; Miyagawa M; Hashida K
Am Heart J; 1996 Jul; 132(1 Pt 1):23-9. PubMed ID: 8701872
[TBL] [Abstract][Full Text] [Related]
14. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
Ivandic B; Castellani LW; Wang XP; Qiao JH; Mehrabian M; Navab M; Fogelman AM; Grass DS; Swanson ME; de Beer MC; de Beer F; Lusis AJ
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1284-90. PubMed ID: 10323781
[TBL] [Abstract][Full Text] [Related]
15. Hydrolysis of lipoproteins by sPLA2's enhances mitogenesis and eicosanoid release from vascular smooth muscle cells: Diverse activity of sPLA2's IIA, V and X.
Pruzanski W; Kopilov J; Kuksis A
Prostaglandins Other Lipid Mediat; 2016 Jan; 122():64-8. PubMed ID: 26711221
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFα-stimulated human endothelial cells and reduce associated atherogenicity.
Sonoki K; Iwase M; Ohdo S; Ieiri I; Matsuyama N; Takata Y; Kitazono T
J Cardiovasc Pharmacol; 2012 Oct; 60(4):367-74. PubMed ID: 22743636
[TBL] [Abstract][Full Text] [Related]
17. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.
Wootton PT; Arora NL; Drenos F; Thompson SR; Cooper JA; Stephens JW; Hurel SJ; Hurt-Camejo E; Wiklund O; Humphries SE; Talmud PJ
Hum Mol Genet; 2007 Jun; 16(12):1437-44. PubMed ID: 17545304
[TBL] [Abstract][Full Text] [Related]
18. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
[TBL] [Abstract][Full Text] [Related]
19. Potential involvement of type II phospholipase A2 in atherosclerosis.
Hurt-Camejo E; Camejo G
Atherosclerosis; 1997 Jul; 132(1):1-8. PubMed ID: 9247353
[No Abstract] [Full Text] [Related]
20. [Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease].
Pirkova AA; Samoĭlova EV; Ameliushkina VA; Kaminnyĭ AI; Titov VN; Prokazova NV; Naumov VG; Kucharchuk VV; Korotaeva AA
Kardiologiia; 2007; 47(4):37-40. PubMed ID: 18260836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
